JP5943993B2 - 転写のシグナル伝達及び活性化因子３（ｓｔａｔ３）発現の調節 - Google Patents

転写のシグナル伝達及び活性化因子３（ｓｔａｔ３）発現の調節 Download PDF

Info

Publication number
JP5943993B2
JP5943993B2 JP2014502867A JP2014502867A JP5943993B2 JP 5943993 B2 JP5943993 B2 JP 5943993B2 JP 2014502867 A JP2014502867 A JP 2014502867A JP 2014502867 A JP2014502867 A JP 2014502867A JP 5943993 B2 JP5943993 B2 JP 5943993B2
Authority
JP
Japan
Prior art keywords
stat3
isis
antisense
cells
wing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014502867A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014511686A (ja
JP2014511686A5 (enExample
Inventor
スウェイジ，エリック・イー
フレアー，スーザン・エム
マクラウド，ロバート・エイ
キム，ヨンス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ionis Pharmaceuticals Inc
Original Assignee
Ionis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ionis Pharmaceuticals Inc filed Critical Ionis Pharmaceuticals Inc
Publication of JP2014511686A publication Critical patent/JP2014511686A/ja
Publication of JP2014511686A5 publication Critical patent/JP2014511686A5/ja
Application granted granted Critical
Publication of JP5943993B2 publication Critical patent/JP5943993B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3525—MOE, methoxyethoxy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
JP2014502867A 2011-04-01 2012-03-30 転写のシグナル伝達及び活性化因子３（ｓｔａｔ３）発現の調節 Active JP5943993B2 (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201161471035P 2011-04-01 2011-04-01
US201161471015P 2011-04-01 2011-04-01
US201161471045P 2011-04-01 2011-04-01
US201161471001P 2011-04-01 2011-04-01
US61/471,045 2011-04-01
US61/471,035 2011-04-01
US61/471,001 2011-04-01
US61/471,015 2011-04-01
US201161558316P 2011-11-10 2011-11-10
US201161558308P 2011-11-10 2011-11-10
US61/558,308 2011-11-10
US61/558,316 2011-11-10
PCT/US2012/031642 WO2012135736A2 (en) 2011-04-01 2012-03-30 Modulation of signal transducer and activator of transcription 3 (stat3) expression

Publications (3)

Publication Number Publication Date
JP2014511686A JP2014511686A (ja) 2014-05-19
JP2014511686A5 JP2014511686A5 (enExample) 2015-04-09
JP5943993B2 true JP5943993B2 (ja) 2016-07-05

Family

ID=46932413

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014502867A Active JP5943993B2 (ja) 2011-04-01 2012-03-30 転写のシグナル伝達及び活性化因子３（ｓｔａｔ３）発現の調節

Country Status (35)

Country Link
US (4) US8816056B2 (enExample)
EP (2) EP3466960A3 (enExample)
JP (1) JP5943993B2 (enExample)
KR (2) KR102050469B1 (enExample)
CN (2) CN103562215B (enExample)
AU (1) AU2012236206C1 (enExample)
BR (1) BR112013024768B1 (enExample)
CA (1) CA2831915C (enExample)
CL (1) CL2013002773A1 (enExample)
CO (1) CO6821885A2 (enExample)
CY (1) CY1121460T1 (enExample)
DK (1) DK2697243T3 (enExample)
DO (1) DOP2013000216A (enExample)
EA (2) EA201792185A3 (enExample)
EC (1) ECSP13012909A (enExample)
ES (1) ES2709495T3 (enExample)
GT (1) GT201300232A (enExample)
HR (1) HRP20182169T1 (enExample)
HU (1) HUE042173T2 (enExample)
IL (2) IL228569A (enExample)
LT (1) LT2697243T (enExample)
ME (1) ME03317B (enExample)
MX (1) MX340086B (enExample)
MY (1) MY163004A (enExample)
NI (1) NI201300101A (enExample)
PE (2) PE20181518A1 (enExample)
PH (1) PH12013502049A1 (enExample)
PL (1) PL2697243T3 (enExample)
PT (1) PT2697243T (enExample)
RS (1) RS58489B1 (enExample)
SG (1) SG193504A1 (enExample)
SI (1) SI2697243T1 (enExample)
SM (1) SMT201900060T1 (enExample)
WO (1) WO2012135736A2 (enExample)
ZA (1) ZA201308153B (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS58489B1 (sr) 2011-04-01 2019-04-30 Ionis Pharmaceuticals Inc Modulacija eksprimiranja transduktora signala i aktivatora transkripcije 3 (stat3)
US9410156B2 (en) * 2012-03-28 2016-08-09 Somalogic, Inc. Aptamers to PDGF and VEGF and their use in treating PDGF and VEGF mediated conditions
WO2014062736A1 (en) 2012-10-15 2014-04-24 Isis Pharmaceuticals, Inc. Methods for monitoring c9orf72 expression
RU2730677C2 (ru) 2012-10-15 2020-08-24 Ионис Фармасьютикалз, Инк. Соединение для модуляции экспрессии гена c9orf72 и его применение
WO2014070868A1 (en) * 2012-10-31 2014-05-08 Isis Pharmaceuticals Inc Cancer treatment
CA2921162A1 (en) 2013-05-01 2014-11-06 Ionis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
ES2787600T3 (es) * 2013-07-02 2020-10-16 Ionis Pharmaceuticals Inc Moduladores del receptor de la hormona del crecimiento
EP3044334B1 (en) 2013-09-09 2020-08-12 Somalogic, Inc. Pdgf and vegf aptamers having improved stability and their use in treating pdgf and vegf mediated diseases and disorders
SG10201808903UA (en) 2013-10-11 2018-11-29 Ionis Pharmaceuticals Inc Compositions for modulating c9orf72 expression
MX382230B (es) 2014-05-01 2025-03-13 Ionis Pharmaceuticals Inc Composiciones y metodos para modular la expresion de similar a la angiopoyetina tipo 3.
US10280423B2 (en) 2014-05-01 2019-05-07 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating complement factor B expression
AU2015252841B2 (en) 2014-05-01 2020-03-19 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating growth hormone receptor expression
US10570169B2 (en) 2014-05-22 2020-02-25 Ionis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
US10731163B2 (en) * 2014-09-02 2020-08-04 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft Oligonucleotide targeted to the A20-3′ untranslated region
ES2727154T3 (es) 2014-10-24 2019-10-14 Astrazeneca Ab Combinación
SI3283080T1 (sl) * 2015-04-16 2020-06-30 Ionis Pharmaceuticals, Inc. Sestavki za moduliranje izražanja C9ORF72
CA2991052A1 (en) * 2015-07-02 2017-01-05 City Of Hope Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof
PE20180800A1 (es) 2015-07-10 2018-05-09 Ionis Pharmaceuticals Inc Moduladores de diaciglicerol aciltransferasa 2 (dgat2)
SG11201802718PA (en) 2015-10-14 2018-05-30 Bio Path Holdings Inc P-ethoxy nucleic acids for liposomal formulation
US11260073B2 (en) 2015-11-02 2022-03-01 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating C90RF72
EP3370708A4 (en) 2015-11-06 2019-06-26 Ionis Pharmaceuticals, Inc. MODULATION OF APOLIPOPROTEIN (A) EXPRESSION
WO2017078099A1 (ja) * 2015-11-06 2017-05-11 東レ株式会社 癌の治療及び／又は予防用医薬組成物
WO2017188898A1 (en) 2016-04-29 2017-11-02 Nanyang Technological University G-quadruplex-containing antisense oligonucleotides
CN105985961B (zh) * 2016-07-22 2019-01-29 广西师范大学 抑制EGFR基因表达的siRNA及其应用
CN109963571A (zh) 2016-09-16 2019-07-02 拜奥-帕斯控股股份有限公司 含有脂质体反义寡核苷酸的组合疗法
KR20190065341A (ko) 2016-10-06 2019-06-11 아이오니스 파마수티컬즈, 인코포레이티드 올리고머 화합물들의 접합 방법
AU2017368050A1 (en) 2016-11-29 2019-06-20 Puretech Lyt, Inc. Exosomes for delivery of therapeutic agents
AU2018255352B2 (en) * 2017-04-19 2023-11-16 Bio-Path Holdings, Inc. P-ethoxy nucleic acids for STAT3 inhibition
EA201992490A1 (ru) 2017-04-19 2020-03-03 Байо-Пат Холдингз, Инк. Р-этокси нуклеиновые кислоты для ингибирования bcl2
GB2574793B (en) * 2018-05-01 2022-09-28 Flexenable Ltd Organic liquid crystal display device with one or more oxygen permeable films
TWI869213B (zh) * 2018-09-19 2025-01-01 美商Ionis製藥公司 Pnpla3表現之調節劑
WO2021030769A1 (en) * 2019-08-14 2021-02-18 Codiak Biosciences, Inc. Extracellular vesicles with nras antisense oligonucleotides
CN114514037B (zh) 2019-09-30 2024-12-27 阿斯利康(瑞典)有限公司 用于癌症的组合治疗
EP4058152A4 (en) 2019-11-14 2024-05-08 The Board of Regents of the University of Oklahoma PROSTATE CANCER TREATMENTS USING OLIGONUCLEOTIDES INTERFERENCE
CN115297850A (zh) * 2019-12-05 2022-11-04 得克萨斯州大学系统董事会 用于肝纤维化和其他与纤维化相关的疾病的基于外排体的治疗
US20230127437A1 (en) * 2020-01-31 2023-04-27 Sanwa Kagaku Kenkyusho Co., Ltd. Antisense oligonucleotide of atn1
CN114908094B (zh) * 2022-05-31 2024-03-12 中山大学 一类反义寡核苷酸分子及其在制备治疗恶性肿瘤药物中的应用
WO2024003241A1 (en) 2022-06-30 2024-01-04 Astrazeneca Ab Treatment for immuno-oncology resistant subjects with an anti pd-l1 antibody an antisense targeted to stat3 and an inhibitor of ctla-4

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2699808A (en) 1944-10-06 1955-01-18 Mark W Lowe Apparatus for peeling tomatoes
US2699508A (en) 1951-12-21 1955-01-11 Selectronics Inc Method of mounting and construction of mounting for low frequency piezoelectric crystals
US6582908B2 (en) 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
AU2580892A (en) 1991-09-05 1993-04-05 Isis Pharmaceuticals, Inc. Determination of oligonucleotides for therapeutics, diagnostics and research reagents
RU95114435A (ru) 1992-12-14 1997-05-20 Ханивелл Инк. (Us) Система с бесщеточным двигателем постоянного тока
US5801154A (en) 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
EP0676469A3 (en) 1994-04-04 1998-03-25 Tadamitsu Kishimoto Transcription Factor APRF
AU2549995A (en) 1994-05-16 1995-12-05 Brigham And Women's Hospital Processes, apparatus and compositions for characterizing nucleotide sequences
EP0717110A1 (en) 1994-11-22 1996-06-19 Association Francaise Contre Les Myopathies LGMD gene
US5877021A (en) 1995-07-07 1999-03-02 Ribozyme Pharmaceuticals, Inc. B7-1 targeted ribozymes
US5656408A (en) 1996-04-29 1997-08-12 Xerox Corporation Coated carrier particles
AU4723797A (en) 1997-01-10 1998-08-03 Tadamitsu Kishimoto Novel stat function-regulatory protein
US6770748B2 (en) 1997-03-07 2004-08-03 Takeshi Imanishi Bicyclonucleoside and oligonucleotide analogue
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
CA2303299C (en) 1997-09-12 2016-02-23 Exiqon A/S Oligonucleotide analogues
US20030228597A1 (en) 1998-04-13 2003-12-11 Cowsert Lex M. Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation
US7098192B2 (en) * 1999-04-08 2006-08-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of STAT3 expression
US6159694A (en) 1999-04-08 2000-12-12 Isis Pharmaceuticals Inc. Antisense modulation of stat3 expression
NZ514348A (en) 1999-05-04 2004-05-28 Exiqon As L-ribo-LNA analogues
US6525191B1 (en) 1999-05-11 2003-02-25 Kanda S. Ramasamy Conformationally constrained L-nucleosides
AU1368300A (en) 1999-07-09 2001-01-30 Universite De Liege Cold-active beta galactosidase, the process for its preparation and the use thereof
US6248586B1 (en) 1999-12-17 2001-06-19 Isis Pharmaceuticals, Inc. Antisense modulation of PKA catalytic subunit C-alpha expression
EP1390383B1 (en) 2001-05-11 2012-02-29 Isis Pharmaceuticals, Inc. Antisense permeation enhancers
US20050196781A1 (en) 2001-05-18 2005-09-08 Sirna Therapeutics, Inc. RNA interference mediated inhibition of STAT3 gene expression using short interfering nucleic acid (siNA)
JP2005504020A (ja) 2001-07-03 2005-02-10 アイシス・ファーマシューティカルス・インコーポレーテッド ヌクレアーゼ耐性キメラオリゴヌクレオチド
JP2005516586A (ja) 2001-07-20 2005-06-09 ボード オブ トラスティーズ オブ ザ ユニヴァースティ オブ イリノイ 癌の処置に対する遺伝子標的を同定するための試薬および方法
US7259150B2 (en) * 2001-08-07 2007-08-21 Isis Pharmaceuticals, Inc. Modulation of apolipoprotein (a) expression
WO2004043979A2 (en) 2002-11-05 2004-05-27 Isis Pharmaceuticals, Inc. Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
WO2004041889A2 (en) 2002-11-05 2004-05-21 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
JP2006507841A (ja) 2002-11-14 2006-03-09 ダーマコン， インコーポレイテッド 機能的ｓｉＲＮＡおよび超機能的ｓｉＲＮＡ
WO2004106356A1 (en) 2003-05-27 2004-12-09 Syddansk Universitet Functionalized nucleotide derivatives
EP1661905B9 (en) 2003-08-28 2012-12-19 IMANISHI, Takeshi Novel artificial nucleic acids of n-o bond crosslinkage type
JP5379347B2 (ja) 2003-09-18 2013-12-25 アイシス ファーマシューティカルズ， インコーポレーテッド ４’−チオヌクレオシドおよびオリゴマー化合物
CN100357436C (zh) * 2005-07-01 2007-12-26 中国人民解放军第三军医大学 抑制Stat3基因表达的siRNA及其制备方法
CN1733916A (zh) * 2005-07-01 2006-02-15 中国人民解放军第三军医大学 抑制Stat3基因表达的siRNA及其制备方法
ES2351674T3 (es) 2006-01-27 2011-02-09 Isis Pharmaceuticals, Inc. Análogos de ácidos nucleicos bicíclicos modificados en la posición 6.
CA2651453C (en) 2006-05-11 2014-10-14 Isis Pharmaceuticals, Inc. 5'-modified bicyclic nucleic acid analogs
WO2008101157A1 (en) 2007-02-15 2008-08-21 Isis Pharmaceuticals, Inc. 5'-substituted-2'-f modified nucleosides and oligomeric compounds prepared therefrom
US20100105134A1 (en) 2007-03-02 2010-04-29 Mdrna, Inc. Nucleic acid compounds for inhibiting gene expression and uses thereof
WO2008109494A1 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting stat3 gene expression and uses thereof
EP2170917B1 (en) 2007-05-30 2012-06-27 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
EP2173760B2 (en) 2007-06-08 2015-11-04 Isis Pharmaceuticals, Inc. Carbocyclic bicyclic nucleic acid analogs
EP2176280B2 (en) 2007-07-05 2015-06-24 Isis Pharmaceuticals, Inc. 6-disubstituted bicyclic nucleic acid analogs
JP2010538660A (ja) * 2007-09-17 2010-12-16 イントラドイグム コーポレーション ＳＴＡＴ３ｓｉＲＮＡ含有組成物及びそれらの使用法
AT507215B1 (de) 2009-01-14 2010-03-15 Boehler Edelstahl Gmbh & Co Kg Verschleissbeständiger werkstoff
RS58489B1 (sr) 2011-04-01 2019-04-30 Ionis Pharmaceuticals Inc Modulacija eksprimiranja transduktora signala i aktivatora transkripcije 3 (stat3)
US9984408B1 (en) 2012-05-30 2018-05-29 Amazon Technologies, Inc. Method, medium, and system for live video cooperative shopping
WO2014070868A1 (en) 2012-10-31 2014-05-08 Isis Pharmaceuticals Inc Cancer treatment
US9778708B1 (en) 2016-07-18 2017-10-03 Lenovo Enterprise Solutions (Singapore) Pte. Ltd. Dual sided latching retainer for computer modules

Also Published As

Publication number Publication date
SI2697243T1 (sl) 2019-05-31
RS58489B1 (sr) 2019-04-30
IL228569A (en) 2017-12-31
EP3466960A3 (en) 2019-04-24
CY1121460T1 (el) 2020-05-29
EP2697243B1 (en) 2018-10-31
CN107012144A (zh) 2017-08-04
GT201300232A (es) 2015-02-11
LT2697243T (lt) 2019-04-10
CO6821885A2 (es) 2013-12-31
US20120277284A1 (en) 2012-11-01
US10479993B2 (en) 2019-11-19
PH12013502049A1 (en) 2013-12-16
EP2697243A2 (en) 2014-02-19
EP2697243A4 (en) 2015-04-01
ECSP13012909A (es) 2013-12-31
CA2831915A1 (en) 2012-10-04
BR112013024768A2 (pt) 2018-06-05
MY163004A (en) 2017-07-31
NZ616036A (en) 2015-09-25
JP2014511686A (ja) 2014-05-19
US9359608B2 (en) 2016-06-07
EA201792185A2 (ru) 2018-06-29
US20200385716A1 (en) 2020-12-10
PT2697243T (pt) 2019-01-29
IL228569A0 (en) 2013-12-31
SMT201900060T1 (it) 2019-02-28
WO2012135736A2 (en) 2012-10-04
CA2831915C (en) 2021-01-12
CN103562215B (zh) 2017-04-26
DOP2013000216A (es) 2013-12-15
CL2013002773A1 (es) 2014-04-04
EP3466960A2 (en) 2019-04-10
KR20190092590A (ko) 2019-08-07
KR20140027205A (ko) 2014-03-06
CN103562215A (zh) 2014-02-05
EA201792185A3 (ru) 2018-10-31
KR102050469B1 (ko) 2019-12-02
AU2012236206B2 (en) 2015-09-17
PL2697243T3 (pl) 2019-05-31
PE20181518A1 (es) 2018-09-21
ME03317B (me) 2019-10-20
PE20142463A1 (es) 2015-01-22
HUE042173T2 (hu) 2019-06-28
MX340086B (es) 2016-06-24
US8816056B2 (en) 2014-08-26
DK2697243T3 (en) 2019-02-11
NI201300101A (es) 2014-07-08
MX2013011423A (es) 2014-04-30
US20140336237A1 (en) 2014-11-13
ES2709495T3 (es) 2019-04-16
AU2012236206A1 (en) 2013-05-02
WO2012135736A3 (en) 2012-12-06
US20160348104A1 (en) 2016-12-01
EA201391329A1 (ru) 2014-07-30
IL255858A (en) 2018-01-31
HRP20182169T1 (hr) 2019-04-19
BR112013024768B1 (pt) 2022-02-08
AU2012236206C1 (en) 2018-03-08
SG193504A1 (en) 2013-10-30
ZA201308153B (en) 2016-01-27
EA029317B1 (ru) 2018-03-30

Similar Documents

Publication Publication Date Title
US10479993B2 (en) Modulation of signal transducer and activator of transcription 3 (STAT3) expression
RU2689548C2 (ru) Лечение рака
JP6280045B2 (ja) 肺腺癌内転移関連性転写物１（ｍｅｔａｓｔａｓｉｓ−ａｓｓｏｃｉａｔｅｄ−ｉｎ−ｌｕｎｇ−ａｄｅｎｏｃａｒｃｉｎｏｍａ−ｔｒａｎｓｃｒｉｐｔ−１：ｍａｌａｔ−１）の発現調節法
IL257989B2 (en) Compounds and methods for modulating angiotensinogen expression
JP2015507924A (ja) 第ｖｉｉ因子の発現を調節するための方法と組成物
WO2012174476A2 (en) Antisense modulation of fibroblast growth factor receptor 4 expression
JP5951752B2 (ja) Ｐｔｐ１ｂ発現のアンチセンス調節
HK40007095A (en) Modulation of signal transducer and activator of transcription 3 (stat3) expression
HK40120876A (en) Compounds and methods for modulating angiotensinogen expression
HK1193824A (en) Modulation of signal transducer and activator of transcription 3 (stat3) expression
HK1193824B (en) Modulation of signal transducer and activator of transcription 3 (stat3) expression
NZ616036B2 (en) Modulation of signal transducer and activator of transcription 3 (stat3) expression
HK40069167A (en) Compounds and methods for modulating angiotensinogen expression
HK40008833A (en) Cancer treatment

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150219

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160318

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160412

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160511

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160524

R150 Certificate of patent or registration of utility model

Ref document number: 5943993

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250